Become Affiliate

PepFlow

Download

The VAT Reducer

Tesamorelin

A growth hormone-releasing hormone analog whose clinical identity centers on excess abdominal fat in HIV-associated lipodystrophy and downstream GH/IGF-1 signaling.

Visceral fatGH pulseBody composition
TierA
EvidenceStrong
SafetyWell-Studied
FDA statusApproved
Last reviewed August 17, 2026 42 citations How to read these labels

What is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone that stimulates pituitary GH release and downstream IGF-1. It belongs with GHRH analogs rather than ghrelin-receptor GHRPs such as ipamorelin, GHRP-2, or GHRP-6.[33][34]

The molecule is built around an upstream endocrine signal: cue the pituitary, raise GH pulsatility, and let downstream IGF-1 and metabolic effects carry the clinical question. That upstream position is why glucose, IGF-1, fluid retention, and growth-signal monitoring matter.[33][12]

Product names matter for tesamorelin. EGRIFTA SV and EGRIFTA WR are both tesamorelin products, but they are different formulations with different dose, reconstitution, storage, and administration instructions. The molecule should be understood together with the specific product form.[33][34]

What Tesamorelin is investigated for

Tesamorelin evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Visceral fat reduction in HIV lipodystrophy

Injectable

86%Strong

Visceral-fat reduction in HIV-associated lipodystrophy is the highest-confidence tesamorelin use and should stay population-specific.[33][2][5]

Human evidence

Randomized trials and labeling support reduced excess abdominal fat in adults with HIV-associated lipodystrophy.[33][2][5]

Animal / mechanistic evidence

The GHRH mechanism stimulates GH/IGF-1 signaling, which is tied to the visceral-fat effect and monitoring needs.[33][2][5]

GH-axis stimulation and IGF-1 response

Injectable

68%Moderate

The GH/IGF-1 mechanism is strong, but hormone response alone does not establish broad wellness benefit.[33][12]

Human evidence

Human labeling and trials show GH-axis activity and IGF-1 response, but outcome claims depend on the population studied.[33][12]

Animal / mechanistic evidence

GHRH receptor agonism explains the GH and IGF-1 response.[33][12]

Fat and lean-mass outcomes outside HIV lipodystrophy

Injectable

50%Emerging

Outside HIV lipodystrophy, fat and lean-mass claims should stay study-specific and monitored rather than generalized to healthy-aging use.[14][23]

Human evidence

Small randomized studies in obese adults with reduced GH secretion and in adults with HIV report fat, lean-mass, or muscle-fat findings, but populations and endpoints differ from general wellness use.[14][23][16]

Animal / mechanistic evidence

GHRH receptor agonism and downstream GH/IGF-1 signaling provide the fat and lean-mass rationale.[33][12]

Liver fat and NAFLD

Injectable

50%Emerging

Liver-fat claims should stay HIV-associated NAFLD-specific until broader liver endpoint data exist.[24][26]

Human evidence

Randomized HIV-associated NAFLD studies report liver-fat and fibrosis-related signals, but hard liver outcomes and broader populations remain uncertain.[17][24][26]

Animal / mechanistic evidence

GH-axis and visceral-fat effects provide a plausible metabolic link.[17][24]

Cognitive function

Injectable

38%Preliminary

Cognitive findings are exploratory and should not be presented as cognitive enhancement.[13][30]

Human evidence

Small GHRH and tesamorelin studies have evaluated cognitive or neurocognitive endpoints, but findings remain exploratory.[13][15][30]

Animal / mechanistic evidence

GH/GHRH signaling gives a plausible neuroendocrine rationale, but it is not a direct cognitive-enhancement mechanism.[13][15]

Evidence snapshot

85%

Human evidence

Strong

Randomized trials and FDA labeling support visceral adipose tissue reduction in HIV-associated lipodystrophy.[2][3][5]

65%

Animal / preclinical

Moderate

Nonclinical pharmacology explains GHRH analog action, while the practical evidence base comes mainly from human trials and labeling.[33]

82%

Mechanism support

Strong

GHRH receptor stimulation links tesamorelin to GH release, IGF-1 elevation, and visceral-fat changes in the approved population.[33][12]

Forms & administration

Tesamorelin is tracked with one unbranded vial-and-syringe calculator preset based on the 2 mg once-daily dose used in randomized human trials.[5]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 2 mg per dose.[5]

Frequency

Usually taken once daily.[5]

Timing Considerations

Evening is the usual timing.[5]

Cycle Length

Treatment commonly runs for at least 180 days.[3][5]

What to expect

Weeks 4-8

Injectable label-based treatment may first show waist or abdominal-fullness changes while glucose and IGF-1 labs provide context.[33]

Weeks 12-26

Visceral-fat and waist trends are most meaningful over the clinical-trial window, where pivotal studies used CT-measured VAT.[2][5]

After stopping

Abdominal-fat benefit can move back toward baseline when treatment stops, so maintenance decisions matter.[3]

Safety profile

Tesamorelin has prescription-label safety context for injectable treatment. Practical safety attention belongs on injection-site tolerance, musculoskeletal symptoms, glucose intolerance or diabetes monitoring, IGF-1 elevation, active malignancy, pregnancy, and label-specific contraindications.[33][34]

Common side effects

  • Injection-site pain or swelling[33]
  • Joint discomfort[33]
  • Muscle discomfort[33]

Cautions

  • Active malignancy[33]
  • Pituitary-axis conditions[33]
  • Glucose monitoring[33]

What we don't know

Long-term cardiovascular safety has not been established in labeling.[33]

Who Tesamorelin is not for

Route-specific avoid and medical-review notes:

  • Active malignancy

    Tesamorelin labeling includes active malignancy as a contraindication.[33]

  • Pregnancy

    Tesamorelin is contraindicated in pregnancy because visceral fat reduction offers no benefit and may cause fetal harm.[33]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

  • Diabetes medications

    Injectable tesamorelin can worsen glucose tolerance, so diabetes therapy and glucose labs may need adjustment during treatment.[33]

Theoretical interactions

  • Other GH-axis agents

    GH, GHRPs, or other GHRH analogs can add overlapping IGF-1 and fluid-retention effects with injectable tesamorelin; this is a stack-level safety caution.[33]

Pairing notes

Not recommended with

Somatropin: compounded GH/IGF-1 effectsInjectable

Tesamorelin increases the body's own growth-hormone release, while somatropin supplies growth hormone directly. Using both can compound GH/IGF-1, fluid-retention, and glucose effects.[33][38]

CJC-1295: overlapping GHRH signalingInjectable

Tesamorelin and CJC-1295 both stimulate GHRH receptors to increase growth-hormone and IGF-1 signaling. Using both duplicates the same upstream GH-axis mechanism without an established combined regimen.[34][39][40]

Sermorelin: overlapping GHRH signalingInjectable

Tesamorelin and sermorelin both activate GHRH-receptor signaling and increase endogenous growth-hormone release. Their different formulations do not establish a benefit from overlapping use.[34][41][42]

How it works

Tesamorelin is a GHRH analog that stimulates pituitary GHRH receptors, increasing pulsatile growth hormone release and downstream IGF-1. In its approved context, that GH-axis signal is tied to reduced excess abdominal visceral fat in adults with HIV-associated lipodystrophy.[33][12][5]

The same pathway explains the label cautions: IGF-1 can rise, glucose tolerance can change, fluid-retention symptoms can occur, and neoplasm history matters. Subcutaneous delivery and the labeled population are part of the mechanism interpretation; it should not be generalized to ordinary weight loss or anti-aging.[33][34]

Research gaps & open questions

What the current literature has not yet settled about Tesamorelin:

01

Long-term cardiovascular safety remains unclear beyond the available label and extension data, including risks such as heart attack or stroke.[33]

02

Each off-label use—general fat loss, fatty liver disease, cognition, or nerve injury—needs its own trials; evidence from HIV-related abdominal fat cannot establish those benefits.[26][36]

03

Direct comparisons with current obesity and metabolic medicines are scarce, so relative weight loss, side effects, and long-term benefit cannot be inferred.[12]

Common questions

What is tesamorelin approved for?

Tesamorelin is approved as an injectable drug to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.[33][34]

Is tesamorelin a general weight-loss drug?

No. It is not for weight-loss management; the strongest evidence is for adults with HIV-associated lipodystrophy.[33]

Is tesamorelin allowed in tested sports?

No. WADA prohibits tesamorelin and other growth hormone releasing factors under S2 unless a valid anti-doping pathway applies.[38]

Myths & misconceptions

Myth

FDA-approved for visceral fat means tesamorelin is approved for anyone who wants fat loss.

Reality

The approval is specific to excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight management.[33]

Myth

EGRIFTA WR and EGRIFTA SV can be substituted milligram for milligram.

Reality

The labels state the formulations have different dosing, reconstitution, storage, and administration instructions and are not substitutable.[34]

History & discovery

Tesamorelin's history is different from many peptide-library entries because it moved from GHRH analog pharmacology into an FDA-approved, narrowly labeled HIV-lipodystrophy drug.[33][2]

Randomized trials tested whether a growth-hormone-releasing factor analog could reduce visceral adipose tissue in adults with HIV-associated abdominal fat accumulation.[2][5]

The approval history made tesamorelin a regulated prescription product for one specific use, not a general weight-loss or anti-aging peptide.[32][33]

EGRIFTA WR labeling continued the same HIV-lipodystrophy indication while later research explored liver fat and other HIV-associated metabolic questions.[34]

Published research42 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay on track with your weight-management goals.

Use PepFlow to record your Tesamorelin protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00